微外科技术（MST）在2025年ASCRS年会上展示其玻璃体切除术技术的领导地位提升-动脉网

MicroSurgical Technology (MST) Advances Leadership in Vitrectomy Technology with Presentations at ASCRS 2025 Annual Meeting

CISION 等信源发布 2025-04-22 21:03



可切换为仅中文







Research highlights safety and efficacy of Vista 1-Step vitrectomy probe

研究强调了Vista 1-Step玻璃体切除术探针的安全性和有效性

REDMOND, Wash.

红mond，华盛顿州

，

April 22, 2025

2025年4月22日

/PRNewswire/ --

MicroSurgical Technology (MST)

微型外科技术（MST）

, a leader in surgeon-designed, innovative ophthalmic products, announced today that it will share research during two presentations on the Vista 1-Step novel vitrectomy probe at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The meeting takes place

，一家由外科医生设计、创新的眼科产品领域的领导者，今天宣布将在2025年美国白内障和屈光手术学会（ASCRS）年会上通过两场报告分享关于Vista 1-Step新型玻璃体切除探针的研究。会议将于

April 25-28, 2025

2025年4月25日至28日

, at the

，在

Los Angeles

洛杉矶

Convention Center (LACC). Surgeons are invited to visit MST Booth #2631 to learn more about the Vista 1-Step vitrectomy probe, in addition to its full portfolio of ophthalmic instrument technology.

会议中心 (LACC)。外科医生受邀参观MST展位 #2631，以了解更多关于Vista 1-Step玻璃体切除探针的信息，以及其完整的眼科仪器技术产品组合。

The Vista 1-Step, a 27-gauge, 14.5 mm needlepoint single-use vitrector, is designed for a seamless introduction through the sclera. Featuring a dual-blade cutter, it delivers up to 11,000 cuts per minute, connects directly to all major phaco/posterior units, and is intended to be used to remove vitreous and dissect the eye..

Vista 1-Step是一款27号规格、14.5毫米针尖的一次性玻璃体切割器，旨在通过巩膜实现无缝引入。其配备双刀片切割器，每分钟可进行高达11,000次切割，直接连接到所有主要的超声乳化/后节单元，用于去除玻璃体并解剖眼球。

Presentations featuring Vista 1-Step data at ASCRS include:

在ASCRS上展示Vista 1-Step数据的报告包括：

Saturday, April 26

4月26日，星期六

，

8:38 a.m.-8:43 a.m. PDT

上午8点38分至上午8点43分（太平洋夏令时间）

Safety and Performance of a 27-Gauge, 22,000-Cut-per-Minute Vitrectomy Probe for Pars Plana Anterior Vitrectomy

27-Gauge、每分钟22,000切口的玻璃体切除探头在平坦部前玻璃体切除术中的安全性和性能

Presenting author:

报告作者：

Brandon D. Ayres

布兰登·D·艾尔斯

, M.D., ABO

，医学博士，ABO

Location: LACC, Level 2, 512

地点：LACC，2楼，512室

The presentation will highlight the safety and performance of a

报告将重点介绍安全性和性能

510k

-approved, 27-gauge, sharp needle-tip probe for pars plana-assisted anterior vitrectomy (PPAAV) used to address vitreous prolapse during IOL repositioning/exchange or secondary IOL cases. The 1-Step Vitrectomy Probe was rated highly by surgeons for ease of use and vitreous cutting efficiency compared to limbal-based or conventional pars-plana devices..

经批准的27号针头，尖锐针尖探针，用于经平坦部辅助的前玻璃体切除术（PPAAV），在人工晶状体（IOL）重新定位/更换或二次植入IOL时处理玻璃体脱出。与基于角膜缘或传统的经平坦部设备相比，1-Step玻璃体切除探针因易于使用和玻璃体切割效率高而受到外科医生的高度评价。

Sunday, April 27

4月27日，星期日

, 8:30 a.m.-8:35 a.m. PDT

，太平洋时间上午8:30-8:35

Safety and Efficacy Outcomes of a Novel Vitrectomy Device Used to Remove Symptomatic Vitreous Opacities in Pseudophakic Patients

一种新型玻璃体切除设备用于去除假性晶状体患者症状性玻璃体混浊的安全性和有效性结果

Presenting author: Inder P. Singh, M.D.

报告作者：Inder P. Singh，医学博士

Location: LACC, Level 2, 504

地点：LACC，2楼，504室

This presentation will discuss the safety and efficacy outcomes of a novel vitrectomy device used to remove symptomatic vitreous opacities in pseudophakic patients. At 3 months, all 78 eyes demonstrated symptomatic improvement with 86% of the patients reporting complete resolution of symptoms. The other 14% reported improvement, averaging 85%. .

本演示将讨论一种新型玻璃体切除设备的安全性和有效性结果，该设备用于去除假性晶状体患者中出现症状的玻璃体混浊。在3个月时，所有78只眼睛均表现出症状改善，其中86%的患者报告症状完全消失，另外14%的患者报告症状有所改善，平均改善率为85%。

Additionally, MST will host the following activities in Booth #2631 on

此外，MST 将在 #2631 展位举办以下活动

April 26, 2025

2025年4月26日

：

11:00 a.m.

上午11点

–

Inder P. Singh, M.D. will present on the data from his presentation, including a Q&A

因德尔·P·辛格博士将展示他演讲中的数据，并包括问答环节

2:15 p.m.

下午2点15分

–

Brandon D. Ayres, M.D. and

布兰登·D·艾尔斯，医学博士和

Nicole Fram

尼科尔·弗拉姆

, M.D. will discuss Vista 1-Step and other complex cases that use additional MST devices

，医学博士将讨论Vista 1-Step和其他使用额外MST设备的复杂案例。

'We're pleased with the exciting data regarding the benefits of Vista 1-Step,' said MST President and CEO

“我们对关于Vista 1-Step益处的激动人心的数据感到满意，”MST总裁兼首席执行官表示。

Yash Singh

亚什·辛格

. 'Our efforts enable us to provide significant positive impacts for the surgical community with revolutionary, surgeon-inspired products.'

“我们的努力使我们能够通过革命性的、受外科医生启发的产品为外科界提供重大的积极影响。”

Product Designer of Vista 1-Step Jeffrey C. Whitsett, M.D., added, 'The data presented at ASCRS this year highlights the Vista 1-Step's leadership role in providing safe and effective treatment options to remove vitreous and dissect tissue in the eye. Our technology provides a seamless introduction through the sclera without the need for (microvitreoretinal) MVR blades or trocars.' .

Vista 1-Step产品设计师杰弗里·C·惠特塞特医学博士补充道：“今年在ASCRS上展示的数据突显了Vista 1-Step在提供安全有效的治疗方案以去除玻璃体和分离眼部组织方面的领导地位。我们的技术能够无缝穿过巩膜，无需使用（微玻璃体视网膜）MVR刀片或套管。”

About Microsurgical Technology (MST)

关于显微外科技术（MST）

Microsurgical Technology (MST) is a leader in the development of advanced surgical instruments and solutions. With a focus on precision and innovation, MST is dedicated to advancing ophthalmic surgery through innovative and surgeon-inspired products. Their mission is to deliver cutting-edge solutions that address the evolving needs of the ophthalmic community.

Microsurgical Technology（MST）是先进外科手术器械和解决方案开发的领导者。凭借对精确性和创新的关注，MST致力于通过创新且受外科医生启发的产品推动眼科手术的发展。其使命是提供尖端解决方案，满足眼科界不断变化的需求。

For more information, visit .

如需更多信息，请访问。

www.microsurgical.com

。

Media Contact:

媒体联系人：

Shannon Severino

香农·塞维诺

shannon.severino@powers-co.com

香农·塞韦里诺@鲍尔斯公司.com

412-608-2393